ERBB2 and cancer: A patient (patient 21, DL 20 × 106) with carcinosarcoma-type ovarian cancer (HER2 1+, FISH 1.0) who enrolled after five lines of prior cancer treatment had a maximum 24.8% decrease in the sum of target lesions that lasted until week 48.